Mechanisms of Disease

From the Metabolism Branch, National Cancer Institute, Bethesda, MD (G.L., L.M.S.); and the Charité–Humboldt University, Campus Virchow, Department of Hematology–Oncology, Berlin (G.L.). Address reprint requests to Dr. Staudt at the Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bldg. 10, Rm. 4N114, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, or at lstaudt@mail.nih.gov.

[1]  Ronald Levy,et al.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.

[2]  Jan Delabie,et al.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.

[3]  M. Nussenzweig,et al.  AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. , 2009, Molecular cell.

[4]  Ralf Küppers,et al.  Molecular footprints of a germinal center derivation of human IgM+(IgD+)CD27+ B cells and the dynamics of memory B cell generation , 2009, The Journal of experimental medicine.

[5]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[6]  F. Alt,et al.  Mechanisms promoting translocations in editing and switching peripheral B cells , 2009, Nature.

[7]  L. Staudt,et al.  Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. , 2009, Blood.

[8]  L. Pasqualucci,et al.  Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma , 2009, Nature.

[9]  Kenny Q. Ye,et al.  The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. , 2009, Blood.

[10]  Amanda Doucette,et al.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.

[11]  M. Karin,et al.  Regulation and function of NF-kappaB transcription factors in the immune system. , 2009, Annual review of immunology.

[12]  M. Nussenzweig,et al.  AID Is Required for the Chromosomal Breaks in c-myc that Lead to c-myc/IgH Translocations , 2008, Cell.

[13]  M. Lieber,et al.  Human Chromosomal Translocations at CpG Sites and a Theoretical Basis for Their Lineage and Stage Specificity , 2008, Cell.

[14]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[15]  L. Pasqualucci,et al.  The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. , 2008, Blood.

[16]  L. Staudt,et al.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.

[17]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[18]  Jing Wang,et al.  Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes , 2008, Nature Immunology.

[19]  S. Rafii,et al.  Migratory neighbors and distant invaders: tumor-associated niche cells. , 2008, Genes & development.

[20]  Stefano Monti,et al.  SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. , 2008, Blood.

[21]  D. Schatz,et al.  Two levels of protection for the B cell genome during somatic hypermutation , 2008, Nature.

[22]  J. Cyster,et al.  Germinal-center organization and cellular dynamics. , 2007, Immunity.

[23]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[24]  M. Nussenzweig,et al.  ATM Prevents the Persistence and Propagation of Chromosome Breaks in Lymphocytes , 2007, Cell.

[25]  S. Rafii,et al.  The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. , 2007, Trends in immunology.

[26]  J. Vose,et al.  Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. White,et al.  Metabolic catastrophe as a means to cancer cell death , 2007, Journal of Cell Science.

[28]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[29]  D. Rawlings,et al.  The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes , 2006, Nature Reviews Immunology.

[30]  Roger Sciammas,et al.  Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. , 2006, Immunity.

[31]  R. Spang,et al.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.

[32]  E. Kremmer,et al.  Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells. , 2006, Blood.

[33]  Liming Yang,et al.  A loss-of-function RNA interference screen for molecular targets in cancer , 2006, Nature.

[34]  M. Korc,et al.  Connective tissue growth factor–specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer , 2006, Molecular Cancer Therapeutics.

[35]  T. Mattfeldt,et al.  Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation , 2006, Oncogene.

[36]  David Jung,et al.  Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. , 2006, Annual review of immunology.

[37]  Michel C. Nussenzweig,et al.  Role of genomic instability and p53 in AID-induced c-myc–Igh translocations , 2006, Nature.

[38]  Michael M. Murphy,et al.  H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. , 2006, Molecular cell.

[39]  H. Tagawa,et al.  Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. , 2005, Blood.

[40]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[41]  L. Staudt,et al.  Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays , 2005, Leukemia.

[42]  Y. Tu,et al.  Tracking CD40 signaling during germinal center development. , 2004, Blood.

[43]  L. Pasqualucci,et al.  Expression of the AID protein in normal and neoplastic B cells. , 2004, Blood.

[44]  J. Licht,et al.  Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells , 2004, Nature Medicine.

[45]  M. Nussenzweig,et al.  AID Is Required for c-myc/IgH Chromosome Translocations In Vivo , 2004, Cell.

[46]  Somasekar Seshagiri,et al.  De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling , 2004, Nature.

[47]  J. D. Dal Porto,et al.  B cell antigen receptor signaling 101. , 2004, Molecular immunology.

[48]  L. Staudt,et al.  XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. , 2004, Immunity.

[49]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[50]  M. Lieber,et al.  A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex , 2004, Nature.

[51]  T. Golub,et al.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.

[52]  L. Staudt,et al.  Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.

[53]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Andrea Califano,et al.  Transcriptional analysis of the B cell germinal center reaction , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Liming Yang,et al.  Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. , 2002, Immunity.

[56]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[57]  L. Staudt,et al.  Signatures of the immune response. , 2001, Immunity.

[58]  L. Pasqualucci,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[59]  A. Baldwin.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB , 2001 .

[60]  D. Fearon,et al.  Suppression of Signal Transducer and Activator of Transcription 3–Dependent B Lymphocyte Terminal Differentiation by Bcl-6 , 2000, The Journal of experimental medicine.

[61]  T. Honjo,et al.  Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme , 2000, Cell.

[62]  Ash A. Alizadeh,et al.  Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[63]  L. Staudt,et al.  BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. , 2000, Immunity.

[64]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[65]  L. Pasqualucci,et al.  BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[66]  U. Storb,et al.  Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. , 1998, Science.

[67]  M. Hatano,et al.  Disruption of the Bcl6 Gene Results in an Impaired Germinal Center Formation , 1997, The Journal of experimental medicine.

[68]  L. Staudt,et al.  Control of inflammation, cytokine expression, and germinal center formation by BCL-6. , 1997, Science.

[69]  P. L. Bergsagel,et al.  Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Mark M. Davis,et al.  Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells , 1994, Cell.

[71]  F. Batista,et al.  The who, how and where of antigen presentation to B cells , 2009, Nature Reviews Immunology.

[72]  L. Pasqualucci,et al.  AID is required for germinal center–derived lymphomagenesis , 2008, Nature Genetics.

[73]  W. Chan,et al.  Mutational analysis of PRDM 1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas , 2006 .

[74]  S. Monti,et al.  Inactivation of the PRDM 1 / BLIMP 1 gene in diff use large B cell lymphoma , 2006 .

[75]  T. Barth,et al.  Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. , 2005, Blood.

[76]  C. Copie-Bergman,et al.  Constitutive STAT 6 activation in primary mediastinal large B-cell lymphoma , 2004 .

[77]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[78]  M. Woodruff,et al.  Immune Response , 1969, Nature.